Use these materials to familiarize yourself with the information to confidently prescribe TAVALISSE.
Information such as indication, dosing, safety, and efficacy as approved by the FDA.
Learn about the convenience of oral dosing without food restrictions, dosing modifications, and management of certain adverse reactions.
Revew the published results of FIT-1 and FIT-2 in: Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930.
Review the published results of FIT-3 in: Bussel JB, Arnold DM, Boxer MA, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546-553.
Review the published post hoc analysis of the FIT studies in: Boccia R, Cooper N, Ghanima W, et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br J Haematol. 2020;190(6):933-938.
These resources are designed to provide key points of support to patients all the way through their TAVALISSE treatment journey.
This brochure provides information on ITP, how TAVALISSE is different from other therapies, and how TAVALISSE can help patients reach their treatment goals.
This journal offers suggestions to help incorporate TAVALISSE into patients' lifestyles, stay on track with treatment, and monitor progress.
Reviews important information for patients about TAVALISSE, including for whom TAVALISSE is intended, how to take TAVALISSE, and what to expect while on treatment.
Use the TAVALISSE Enrollment and Patient Assistance Program Form as a prescription and to enroll a patient into RIGEL ONECARE and the Patient Assistance Program, if eligible.
Professor of Medicine and Pathology with the Division of Hematology-Oncology, Director of the Division of Coagulation in the Department of Laboratory Medicine at the Georgetown University Medical Center
Founder and Medical Director for the Center for Cancer and Blood Disorders, Chief Medical Officer for the International Oncology Network Clinical Research Program
See how TAVALISSE is believed to inhibit downstream signaling that leads to platelet destruction in chronic ITP.